Briefly, we suggest for AML patients with high BCL-2 levels the venetoclax + I-BET151 combination, which decreases BCL2 gene transcription and BCL-2 protein levels, whereas for AML patients with high MCL-1 levels, the venetoclax + sunitinib combination would be considered for its ability to affect MCL-1 levels. The gene discussed is MCL1; the disease is acute myeloid leukemia.